Literature DB >> 17552028

The interferon inducing pathways and the hepatitis C virus.

Eliane F Meurs1, Adrien Breiman.   

Abstract

The innate immune response is triggered by a variety of pathogens, including viruses, and requires rapid induction of type I interferons (IFN), such as IFNbeta and IFNalpha. IFN induction occurs when specific pathogen motifs bind to specific cellular receptors. In non-professional immune, virally-infected cells, IFN induction is essentially initiated after the binding of dsRNA structures to TLR3 receptors or to intracytosolic RNA helicases, such as RIG-I/MDA5. This leads to the recruitment of specific adaptors, such as TRIF for TLR3 and the mitochondrial-associated IPS-1/VISA/MAVS/CARDIF adapter protein for the RNA helicases, and the ultimate recruitment of kinases, such as MAPKs, the canonical IKK complex and the TBK1/IKKepsilon kinases, which activate the transcription factors ATF-2/c-jun, NF-kappaB and IRF3, respectively. The coordinated action of these transcription factors leads to induction of IFN and of pro-inflammatory cytokines and to the establishment of the innate immune response. HCV can cleave both the adapters TRIF and IPS-1/VISA/MAVS/CARDIF through the action of its NS3/4A protease. This provokes abrogation of the induction of the IFN and cytokine pathways and favours viral propagation and presumably HCV chronic infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552028      PMCID: PMC4146763          DOI: 10.3748/wjg.v13.i17.2446

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  86 in total

1.  5'-Triphosphate RNA is the ligand for RIG-I.

Authors:  Veit Hornung; Jana Ellegast; Sarah Kim; Krzysztof Brzózka; Andreas Jung; Hiroki Kato; Hendrik Poeck; Shizuo Akira; Karl-Klaus Conzelmann; Martin Schlee; Stefan Endres; Gunther Hartmann
Journal:  Science       Date:  2006-10-12       Impact factor: 47.728

2.  The protein kinase IKKepsilon can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV-infected livers.

Authors:  Myriam Vilasco; Esther Larrea; Damien Vitour; Stephanie Dabo; Adrien Breiman; Béatrice Regnault; Jose-Ignacio Riezu; Pierre Eid; Jesus Prieto; Eliane F Meurs
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

3.  TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon-beta.

Authors:  Hiroyuki Oshiumi; Miwa Sasai; Kyoko Shida; Takashi Fujita; Misako Matsumoto; Tsukasa Seya
Journal:  J Biol Chem       Date:  2003-09-30       Impact factor: 5.157

4.  Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA.

Authors:  Sandra S Diebold; Tsuneyasu Kaisho; Hiroaki Hemmi; Shizuo Akira; Caetano Reis e Sousa
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

5.  Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8.

Authors:  Florian Heil; Hiroaki Hemmi; Hubertus Hochrein; Franziska Ampenberger; Carsten Kirschning; Shizuo Akira; Grayson Lipford; Hermann Wagner; Stefan Bauer
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

6.  Does Toll-like receptor 3 play a biological role in virus infections?

Authors:  Kurt H Edelmann; Sarah Richardson-Burns; Lena Alexopoulou; Kenneth L Tyler; Richard A Flavell; Michael B A Oldstone
Journal:  Virology       Date:  2004-05-01       Impact factor: 3.616

7.  An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.

Authors:  Daniel Lamarre; Paul C Anderson; Murray Bailey; Pierre Beaulieu; Gordon Bolger; Pierre Bonneau; Michael Bös; Dale R Cameron; Mireille Cartier; Michael G Cordingley; Anne-Marie Faucher; Nathalie Goudreau; Stephen H Kawai; George Kukolj; Lisette Lagacé; Steven R LaPlante; Hans Narjes; Marc-André Poupart; Jean Rancourt; Roel E Sentjens; Roger St George; Bruno Simoneau; Gerhard Steinmann; Diane Thibeault; Youla S Tsantrizos; Steven M Weldon; Chan-Loi Yong; Montse Llinàs-Brunet
Journal:  Nature       Date:  2003-10-26       Impact factor: 49.962

8.  Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection.

Authors:  Kenya Honda; Shinya Sakaguchi; Chigusa Nakajima; Ai Watanabe; Hideyuki Yanai; Misako Matsumoto; Toshiaki Ohteki; Tsuneyasu Kaisho; Akinori Takaoka; Shizuo Akira; Tsukasa Seya; Tadatsugu Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

9.  Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling.

Authors:  Shintaro Sato; Masanaka Sugiyama; Masahiro Yamamoto; Yasuyuki Watanabe; Taro Kawai; Kiyoshi Takeda; Shizuo Akira
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

10.  Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta.

Authors:  Zhengfan Jiang; Tak W Mak; Ganes Sen; Xiaoxia Li
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

View more
  18 in total

1.  High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection.

Authors:  Michael A Chattergoon; Jordana S Levine; Rachel Latanich; William O Osburn; David L Thomas; Andrea L Cox
Journal:  J Infect Dis       Date:  2011-10-07       Impact factor: 5.226

Review 2.  Function and regulation of retinoic acid-inducible gene-I.

Authors:  Tomoh Matsumiya; Diana M Stafforini
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 3.  Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.

Authors:  Kyle John Wilby; Nilufar Partovi; Jo-Ann E Ford; Erica Greanya; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2012-04       Impact factor: 3.522

4.  Interferon regulatory factor 3 plays a role in macrophage responses to interferon-γ.

Authors:  Zachary P Guinn; Thomas M Petro
Journal:  Immunobiology       Date:  2019-05-02       Impact factor: 3.144

5.  Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer.

Authors:  Sophia S Wang; M Concepcion Bratti; Ana Cecilia Rodríguez; Rolando Herrero; Robert D Burk; Carolina Porras; Paula González; Mark E Sherman; Sholom Wacholder; Z Elizabeth Lan; Mark Schiffman; Stephen J Chanock; Allan Hildesheim
Journal:  J Infect Dis       Date:  2009-01-01       Impact factor: 5.226

6.  Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.

Authors:  Celia Perales; Nathan M Beach; Isabel Gallego; Maria Eugenia Soria; Josep Quer; Juan Ignacio Esteban; Charles Rice; Esteban Domingo; Julie Sheldon
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

7.  Possible association of VISA gene polymorphisms with susceptibility to systemic lupus erythematosus in Chinese population.

Authors:  Xiaowen Liu; Yulian Jiao; Xin Wen; Laicheng Wang; Chunyan Ma; Xuejun Gao; Zi-Jiang Chen; Yueran Zhao
Journal:  Mol Biol Rep       Date:  2010-12-02       Impact factor: 2.742

8.  Core as a novel viral target for hepatitis C drugs.

Authors:  Arthur Donny Strosberg; Smitha Kota; Virginia Takahashi; John K Snyder; Guillaume Mousseau
Journal:  Viruses       Date:  2010-08-20       Impact factor: 5.818

9.  Natural killer cell functional dichotomy: a feature of chronic viral hepatitis?

Authors:  Mario U Mondelli; Barbara Oliviero; Dalila Mele; Stefania Mantovani; Chiara Gazzabin; Stefania Varchetta
Journal:  Front Immunol       Date:  2012-11-26       Impact factor: 7.561

10.  Inhibition of HCV by the serpin antithrombin III.

Authors:  Mohammed Asmal; Michael Seaman; Wenyu Lin; Raymond T Chung; Norman L Letvin; Ralf Geiben-Lynn
Journal:  Virol J       Date:  2012-10-02       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.